Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18308683 | 1.00 | KDM4E (0.48) | KDM4EALDH1A1HPGDHSD17B10GLA | |
| SCHEMBL18308686 | 0.88 | ALDH1A1 (0.50) | KDM4EALDH1A1HPGDHSD17B10GLA | |
| SCHEMBL976404 | 0.85 | KDM4E (0.46) | KDM4EALDH1A1HPGDHSD17B10GLA | |
| SCHEMBL12945021 | 0.85 | KDM4E (0.46) | KDM4EALDH1A1HPGDHSD17B10GLA | |
| SCHEMBL12922268 | 0.85 | KDM4E (0.46) | KDM4EALDH1A1HPGDHSD17B10GLA | |
| Hydrochloric Acid SCHEMBL976093 | 0.84 | KDM4E (0.45) | KDM4EALDH1A1HPGDHSD17B10GLA | |
| SCHEMBL975148 | 0.80 | PIK3CD (0.56) | KDM4EALDH1A1HPGDHSD17B10GLA | |
| SCHEMBL976023 | 0.80 | PIK3CD (0.56) | KDM4EALDH1A1HPGDHSD17B10GLA | |
| SCHEMBL973303 | 0.80 | PIK3CG (0.56) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL18308687 | 0.78 | ALDH1A1 (0.42) | KDM4EALDH1A1HPGDHSD17B10GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9732097-B2 | Process for the synthesis of a phosphoinositide 3-kinase inhibitor | INCYTE CORPORATION (US) | 2017-08-15 | — | — | US | disclosed |
| US-20160362426-A1 | PROCESS FOR THE SYNTHESIS OF A PHOSPHOINOSITIDE 3-KINASE INHIBITOR | INCYTE CORPORATION | 2016-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362426-A1 | PROCESS FOR THE SYNTHESIS OF A PHOSPHOINOSITIDE 3-KINASE INHIBITOR | PIK3CA, PI4KA, PIK3CD | KDM4E 1000/4885ALDH1A1 4191/4885HPGD 1788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.